I. M. Ghobrial

Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors

Novel mechanism of MYC deregulation in Multiple Myeloma

The paper identifies a new epigenetic mechanism of MYC deregulation in multiple myeloma through enhancer accessibility and transcription factor binding, independent of translocations or amplifications.

Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma

The paper identifies enhancer dependencies in MYC-intact and MYC-rearranged GCB-DLBCL using CRISPRi screens, revealing distinct regulatory mechanisms.

Single-cell multi-omics defines the cell-type specific impact of splicing aberrations in human hematopoietic clonal outgrowths

This study introduces GoT-Splice, a multi-omics method to analyze splicing aberrations in human hematopoietic cells, revealing cell-type specific effects of SF3B1 mutations in clonal outgrowths.

Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation

This study uses single-cell multi-omics to show DNMT3A R882 mutations cause hypomethylation and alter progenitor cell fates in clonal hematopoiesis.

Genetic Subtypes of Smoldering Multiple Myeloma are associated with Distinct Pathogenic Phenotypes and Clinical Outcomes

This study identifies six genetic subtypes of smoldering multiple myeloma associated with distinct clinical outcomes and progression risks.

In Vivo Monitoring of Rare Circulating Tumor Cell and Cluster Dissemination in a Multiple Myeloma Xenograft Model

This study develops a GFP-compatible DiFC method to non-invasively monitor CTC burden and detect CTC clusters in a multiple myeloma xenograft model.

Inhibition of mitochondrial ferredoxin 1 (FDX1) prevents adaptation to proteotoxic stress

This study identifies FDX1 inhibition as a strategy to prevent proteasome inhibitor resistance in cancer by targeting mitochondrial Fe-S cluster biosynthesis.